Issue: November 2017
November 08, 2017
1 min read
Save
Trial Scorecard: PACIFY
Issue: November 2017
Study evaluated effects of anacetrapib (Merck) to reduce risk for MI, coronary death or coronary revascularization in patients with atherosclerotic vascular disease taking statin therapy.
